Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 4, 2014, Pages 352-359

  Yun, Hwi yeol ^a   Kang, Wonku ^b,c   Lee, Byung Yo ^a   Park, Sunkyung ^b   Yoon, Young Ran ^d   Ma, Jin Yeul ^e   Kwon, Kwang Il ^a  

^a Chungnam National University   (South Korea)

^b Yeungnam University   (South Korea)

^c Chung Ang University   (South Korea)

^d Kyungpook National University   (South Korea)

^e Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CILOSTAZOL; CLOPIDOGREL; DRUG METABOLITE; TRIFLUSAL; ANTITHROMBOCYTIC AGENT; SALICYLIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; HUMAN; IN VITRO STUDY; INTRINSIC ACTIVITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTION; SIMULATION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; HALF LIFE TIME; RETROSPECTIVE STUDY; THEORETICAL MODEL; THROMBOCYTE; YOUNG ADULT;

ADULT; BLOOD PLATELETS; HALF-LIFE; HUMANS; MODELS, THEORETICAL; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; SALICYLATES; TETRAZOLES; TICLOPIDINE; YOUNG ADULT;

EID: 84908693046     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12222     Document Type: Article

References (16)

1. Fritz E, Ludwig H, Scheithauer W, Sinzinger H. Shortened platelet half-life in multiple myeloma. Blood 1986;68:514-520.
2. Sorkin EM, Markham A. Cilostazol. Drugs Aging 1999;14:63-71.
3. McNeely W, Goa KL. Triflusal. Drugs 1998;55:823-833.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
5. Woo SK, Kang WK, Kwon KI. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther 2002;71:246-252.
6. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet 1991;16:269-273.
7. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-316.
8. Lee HW, Lim MS, Seong SJ, Lee J, Park J, Seo JJ et al. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert Opin Drug Metab Toxicol 2011;7:1471-1479.
9. Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev 2006;58:1326-1356.
10. Katashima M, Yamada Y, Yamamoto K, Kotaki H, Sato H, Sawada Y et al. Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. J Pharmacokinet Biopharm 1999;27:283-296.
11. Bertrand J, Laffont CM, Mentre F, Chenel M, Comets E. Development of a complex parent-metabolite joint population pharmacokinetic model. AAPS J 2011;13:390-404.
12. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741.
13. Arrebola MM, De la Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sanchez de la Cuesta F. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004;43:74-82.
14. Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofeninduced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008;47:129-137.
15. Varanasi KK, Sridhar V, Potharaju S, Shraddha R, Sivakumar SP, Sabapathi SK et al. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. J Chromatogr B 2008;865:91-98.
16. Satheeshmanikandan TR, Sridhar V, Kanthikiran VV, Swaroopkumar VV, Mukkanti K. Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. Arzneimittelforschung 2012;62:425-432.